2026 NIAID DMID Omnibus Broad Agency Announcement
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIAID
No listed company matched (Materiality N/A)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HHS-NIH-NIAID-BAA2025-1 in this department, oldest first.
- Nov 4, 2024Pre-solicitationOpen
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
This cost-reimbursement contract award was made under full and open competition. This type of contract was selected because costs cannot be adequately defined at the time of contract award.
Who won similar work
16 award notices on SAM.gov in the last 24 months. Matched by: Same office (NATIONAL INSTITUTES OF HEALTH NIAID), same product/service code (PSC) AN12 and NAICS 541715.
Single-winner award sizes (14): middle half $2.4M to $48.0M, median $30.6M; range $10K to $48.0M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| SIA PARTNERS U.S., INC. | 1 | $48.0M | Oct 7, 2026 |
| AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA | 1 | $48.0M | Oct 7, 2026 |
| BCG FEDERAL CORP. | 1 | $48.0M | Oct 7, 2026 |
| FISHER BIOSERVICES INC · $TMO · $42.9B | 1 | $48.0M | Oct 7, 2026 |
| PPD DEVELOPMENT LP | 1 | $48.0M | Oct 7, 2026 |
| ADVANCED BIOSCIENCE LABORATORIES, INC. | 1 | $48.0M | Oct 7, 2026 |
| EMINENT SERVICES CORP | 1 | $32.9M | Mar 30, 2026 |
| DUKE UNIVERSITY Durham NC 27705 USA | 1 | $28.3M | Mar 31, 2025 |
| Quality Biological, Inc | 1 | $25.4M | Apr 9, 2025 |
| FLUID DISCOVERY, INC. | 1 | $2.6M | Aug 29, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 14 past awards, $30.6M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 7, 2026FISHER BIOSERVICES INC$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESMateriality: 0.11% of $TMO revenue (Low) SEC
- Oct 7, 2026PPD DEVELOPMENT LP$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026SIA PARTNERS U.S., INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026BCG FEDERAL CORP.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Oct 7, 2026ADVANCED BIOSCIENCE LABORATORIES, INC.$48.0MVACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASESNo listed company matched (Materiality N/A)
- Mar 30, 2026EMINENT SERVICES CORP$32.9MNIAID CLINICAL PRODUCTS CENTER (CPC)No listed company matched (Materiality N/A)
- Dec 21, 2025BATTELLE MEMORIAL INSTITUTE Dublin OH 43017 USA$10KEvaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious DiseasesNo listed company matched (Materiality N/A)
- Aug 29, 2025FLUID DISCOVERY, INC.$2.6MMultiplexed Nucleic Acid Self-Test for Reproducible and Sensitive HIV DetectionNo listed company matched (Materiality N/A)
- Aug 29, 2025Prompt Diagnostics, Inc.$300K (shared ceiling)Prompt Point-of-Care HIV Viral Load MonitoringShared multiple-award ceiling, not one company's win (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $64K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 8 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 7 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.